CAJ | 학술논문

目的：探讨子宫内膜癌组织中let-7i的表达及临床意义。方法：收集2011年4月—2014年12月河北医科大学第一医院40例子宫内膜癌、20例子宫内膜不典型增生及30例正常子宫内膜组织，采用多聚腺苷酸加尾实时荧光定量逆转录聚合酶链反应[poly（A）-RT-qPCR]检测let-7i在不同子宫内膜组织中的表达，并将检测结果和临床及病理资料进行统计学分析。结果：let-7i在子宫内膜癌组织中的表达低于不典型增生和正常子宫内膜组织，3组间差异有统计学意义（P＜0.01）；不同年龄、病理类型、国际妇产科联盟（FIGO）病理分期、病理分级的子宫内膜癌患者let-7i的表达量差异无统计学意义（P＞0.05），在是否合并高血压、糖尿病，是否淋巴结转移及雌激素受体（ER）、孕激素受体（PR）是否阳性的子宫内膜癌患者中let-7i的表达量差异无统计学意义（P＞0.05）。结论：let-7i在子宫内膜癌组织中低表达，可能调控了子宫内膜癌的发生。
목적：탐토자궁내막암조직중let-7i적표체급림상의의。방법：수집2011년4월—2014년12월하북의과대학제일의원40례자궁내막암、20례자궁내막불전형증생급30례정상자궁내막조직，채용다취선감산가미실시형광정량역전록취합매련반응[poly（A）-RT-qPCR]검측let-7i재불동자궁내막조직중적표체，병장검측결과화림상급병리자료진행통계학분석。결과：let-7i재자궁내막암조직중적표체저우불전형증생화정상자궁내막조직，3조간차이유통계학의의（P＜0.01）；불동년령、병리류형、국제부산과련맹（FIGO）병리분기、병리분급적자궁내막암환자let-7i적표체량차이무통계학의의（P＞0.05），재시부합병고혈압、당뇨병，시부림파결전이급자격소수체（ER）、잉격소수체（PR）시부양성적자궁내막암환자중let-7i적표체량차이무통계학의의（P＞0.05）。결론：let-7i재자궁내막암조직중저표체，가능조공료자궁내막암적발생。
Objective:To investigate the expression of let -7i in endometrial carcinoma tissues and its clinical significance. Methods: Forty cases of endometrial carcinoma, twenty cases of atypical hyperplasia and thirty cases of normal endometrium tissues were collected from 2011 April to 2014 December at The First Hospital of Hebei Medical University. Poly (A)-RT-qPCR was employed to test the expression of let-7i in different endometrial tissues. The statistical analyses were performed between the expression of let-7i and the clinicopathological characteristics. Results: The expression of let-7i was lower in endometrial carcinoma tissues than that of atypical hyperplasia and normal endometrium tissues, and the difference was statistically significant(P<0.01). The expression of let-7i in different age, pathological type, FIGO stages, pathological grades of endometrial carcinoma patients had no significant difference (P>0.05), and its expression in endometrial carcinoma patients whether with hypertension, diabetes, lymph node metastasis and ER-positive, PR-positive had no statistical difference (P>0.05). Conclusions: The expression of let-7i was down-regulated in endometrial carcinoma tissues, and it may regulate the origination of endometrial carcinoma.